Amphetamine-induced striatal dopamine release in schizotypal personality disorder.
Adolescent
Adult
Amphetamine
/ pharmacology
Corpus Striatum
/ diagnostic imaging
Dopamine
/ metabolism
Dopamine Uptake Inhibitors
/ pharmacology
Female
Humans
Male
Memory, Short-Term
/ drug effects
Middle Aged
Positron-Emission Tomography
/ methods
Raclopride
Receptors, Dopamine D2
/ metabolism
Schizotypal Personality Disorder
/ diagnostic imaging
Young Adult
Disorganized symptoms
Dopamine
PET
Positive symptoms
Schizophrenia
Schizotypal personality disorder
Striatum
Working memory
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
23
09
2019
accepted:
18
05
2020
pubmed:
24
6
2020
medline:
29
12
2020
entrez:
24
6
2020
Statut:
ppublish
Résumé
Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. We used positron emission tomography with [ There were no significant group differences in BP In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.
Identifiants
pubmed: 32572588
doi: 10.1007/s00213-020-05561-5
pii: 10.1007/s00213-020-05561-5
doi:
Substances chimiques
DRD2 protein, human
0
Dopamine Uptake Inhibitors
0
Receptors, Dopamine D2
0
Raclopride
430K3SOZ7G
Amphetamine
CK833KGX7E
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2649-2659Subventions
Organisme : NIMH NIH HHS
ID : MH56140
Pays : United States
Organisme : CSRD VA
ID : IK6 CX001738
Pays : United States
Organisme : U.S. Department of Veterans Affairs
ID : I01CX000609
Organisme : CSRD VA
ID : I01 CX001451
Pays : United States
Organisme : CSRD VA
ID : I01 CX002093
Pays : United States